sglt2 inhibitor vs glp 1 inhibitors or GLP-1 receptor agonists as second-line therapy in | VHRM What is the impact of
Description
by 2021, that had fallen to $1.2 billion, and by 2024, a measly $800 million
It is a choice that affects your health trajectory for potentially a year or more
00171-7/asset/5c551207-894e-4601-b8b9-6746ee8f65e5/main.assets/gr2_lrg.jpg)
The right foods can stabilize blood sugar and reduce the bodys demand for insulin over time
An oral option developed by Eli Lilly is expected to hit the market in early 2Q, and analysts expect demand to be high
But this convenience has also created a Wild West of providers, pricing models, and service levels
Meanwhile, a renewed focus on sugary foods and beverages is gaining steam with the advent of these drugs
